Bianca Rocca: Beyond API-CAT – Who Should Continue Anticoagulation, And for How Long?
Bianca Rocca, Editor in Chief at European Heart Journal Cardiovascular Pharmacotherapy, shared on X about a recent article by Marcello Di Nisio and Tzu-Fei Wang, published in European Heart Journal – Cardiovascular Pharmacotherapy, adding:
“Beyond API-CAT: who should continue anticoagulation, and for how long?
API-CAT showed that reduced-dose apixaban preserves efficacy while reducing bleeding during extended anticoagulation for cancer-associated thrombosis. Yet, while it answers how intensely we should anticoagulate, two key questions remain: who should continue treatment and for how long?
In this Viewpoint, Marcello Di Nisio and Tzu-Fei Wang argues that extended anticoagulation should be a dynamic process of benefit-risk reassessment, adapting to cancer status, bleeding risk, prognosis and patients’ preferences.
The future may lie not only in safer doses, but in the right treatment, for the right patient, for the right duration.”
Title: Beyond API-CAT: the remaining challenges of extended anticoagulation for cancer-associated thrombosis
Authors: Marcello Di Nisio, Tzu-Fei Wang

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 14, 2026, 23:53Jacopo Imberti: The Past, Present and Future of Arterial Thrombosis Research
-
Nov 14, 2026, 23:48Shrouk Ramadan: Joining the Editorial Review Board of Clinical and Applied Thrombosis and Hemostasis
-
Nov 14, 2026, 23:46Habib Bennaceur: Moving Towards Fewer Limitations for People Living With Haemophilia
-
Nov 14, 2026, 23:44Paul Healy: EU Approves Frehemgo for Haemophilia A
-
Nov 14, 2026, 23:43Mehak Trehan: ASH 2026 Benign Hematology – Ten Abstracts Through an Indian Lens
-
Nov 14, 2026, 23:33Felipe Magalhaes Furtado: Artificial Intelligence Advances PNH Clone Detection Through Machine Learning
-
Nov 14, 2026, 23:33Mona Alfaraj: International Pathology Day Promotes Education in Hemoglobinopathy Diagnostics
-
Nov 14, 2026, 23:33Alexandros Makis: Exploring Vascular Mechanisms and Therapeutic Targets in β-Thalassemia
-
Nov 14, 2026, 23:32Kalyan Roy: Asundexian Approval Marks a Milestone in Targeted Anticoagulation